TY - JOUR
T1 - Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: Does it work?
AU - van Houdt, R
AU - Koedijk, FDH
AU - Bruisten, SM
AU - de Coul, ELMO
AU - Heijnen, MLA
AU - Waldhober, Q
AU - Veldhuijzen, Irene
AU - Richardus, Jan hendrik
AU - Schutten, M (Martin)
AU - Doornum, Gerard
AU - de Man, Rob
AU - Hahne, SJ
AU - Coutinho, RA
AU - Boot, HJ
PY - 2009
Y1 - 2009
N2 - In November 2002, the Netherlands adopted a vaccination program targeted at behavioural risk groups. Between January 2003 and December 2007, 1386 patients acutely infected with HBV were reported. Reported cases declined from 326 in 2003 to 220 in 2007. Sexual intercourse was the most frequently reported mode of transmission (65%), especially among men having sex with men. Genotypes A and D remained predominant. In total, 40,600 participants were fully vaccinated, the overall compliance was 62%, and the estimated overall program coverage was 12% of the at-risk population. With more effort, more susceptibles may be reached, but the program will not be sufficient to substantially reduce HBV in the Netherlands. Therefore, universal vaccination should be considered. (C) 2009 Elsevier Ltd. All rights reserved.
AB - In November 2002, the Netherlands adopted a vaccination program targeted at behavioural risk groups. Between January 2003 and December 2007, 1386 patients acutely infected with HBV were reported. Reported cases declined from 326 in 2003 to 220 in 2007. Sexual intercourse was the most frequently reported mode of transmission (65%), especially among men having sex with men. Genotypes A and D remained predominant. In total, 40,600 participants were fully vaccinated, the overall compliance was 62%, and the estimated overall program coverage was 12% of the at-risk population. With more effort, more susceptibles may be reached, but the program will not be sufficient to substantially reduce HBV in the Netherlands. Therefore, universal vaccination should be considered. (C) 2009 Elsevier Ltd. All rights reserved.
U2 - 10.1016/j.vaccine.2009.03.072
DO - 10.1016/j.vaccine.2009.03.072
M3 - Article
SN - 0264-410X
VL - 27
SP - 3530
EP - 3535
JO - Vaccine
JF - Vaccine
IS - 27
ER -